Advertisement

Schizophrenia and Other Psychotic Disorders

Chapter

Abstract

Around half of all people with psychosis have a co-occurring substance use problem, a much higher prevalence rate than that found in the general population. Alcohol and cannabis are the most frequently used substances, and multiple substance use is common. This comorbidity has profound implications for the course and treatment of psychotic disorders. People with psychosis who use drugs and alcohol have been reported to have poorer symptomatic and functional outcomes than their non-substance using counterparts: they experience more symptoms, are less likely to be compliant with medication, are at greater risk of relapse and hospitalisation and as a consequence make greater use of mental health services. The causes of this increased comorbidity are not yet fully understood. There is evidence that cannabis may act as a specific trigger for psychosis in some vulnerable individuals but simple broad models of either substance use causing schizophrenia or schizophrenia causing substance use have largely been discredited. Multiple risk factor models of comorbidity have not been adequately tested. Research on treatment development is limited and the findings contradictory: there is preliminary evidence for Clozapine but no evidence to support any one atypical antipsychotic over another. Likewise, despite promising findings for a combination of motivational interviewing and cognitive behavioural therapy there is little evidence for its superiority when compared to other psychosocial interventions. More good-quality longitudinal research is needed.

Keywords

Psychotic Symptom Motivational Interview Psychosocial Intervention Psychotic Disorder Cannabis User 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64:19–28.PubMedGoogle Scholar
  2. 2.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA; 1994.Google Scholar
  3. 3.
    Regier DA, Farmer MF, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:251–2518.Google Scholar
  4. 4.
    Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 1997;54:313–21.PubMedGoogle Scholar
  5. 5.
    Carra G, Johnson S. Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK. A systematic review. Soc Psychiatry Psychiatr Epidemiol. 2008;44(6):429–47.PubMedGoogle Scholar
  6. 6.
    Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, Evans M, et al. Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Aust NZ J Psychiatry. 2000;34:221–36.Google Scholar
  7. 7.
    Korkeila JA, Svirskis T, Heinimaa M, Ristkari T, Huttunen J, Ilonen T, et al. Substance abuse and related diagnoses in early psychosis. Compr Psychiatry. 2005;46:447–52.PubMedGoogle Scholar
  8. 8.
    Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res. 2004;67:157–66.PubMedGoogle Scholar
  9. 9.
    Mauri M, Volonteri L, De Gaspari I, Colasanti A, Brambilla M, Cerruti L. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin Pract Epidemiol Ment Health. 2006;23:2–4.Google Scholar
  10. 10.
    Rossi Menezes P, Ratto LR. Prevalence of substance misuse among individuals with severe mental illness in Sao Paulo. Soc Psychiatry Psychiatr Epidemiol. 2004;39:212–7.PubMedGoogle Scholar
  11. 11.
    Soyka M, Albus M, Kathmann N, Finelli A, Hofstetter S, Holzbach R, et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci. 1993;242:362–72.PubMedGoogle Scholar
  12. 12.
    Weaver T, Madden P, Charles V, Stimson G, Renton A, Tyrer P, et al. Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. Br J Psychiatry. 2003;183:304–13.PubMedGoogle Scholar
  13. 13.
    Baigent M, Holme G, Hafner RJ. Self reports of the interaction between substance abuse and schizophrenia. Aust NZ J Psychiatry. 1995;29:69–74.Google Scholar
  14. 14.
    Dickey B, Azeni H, Weiss R, Sederer L. Schizophrenia, substance use disorders and medical co-morbidity. J Ment Health Policy Econ. 2000;3:27–33.PubMedGoogle Scholar
  15. 15.
    Mahler JC. HIV, substance use and mental illness. In: Lehman AF, Dixon LB, editors. Double jeopardy, chronic mental illness and substance use disorders. London: Harwood Academic; 1995.Google Scholar
  16. 16.
    Goodman LA, Salyers MP, Mueser KT, Rosenberg SD, Swartz M, Essock SM, et al. Recent victimization in women and men with severe mental illness: prevalence and correlates. J Trauma Stress. 2001;14:615–32.PubMedGoogle Scholar
  17. 17.
    Alexander MJ. Women with co-occurring addictive and mental disorders: An emerging profile of vulnerability. Am J Orthopsychiatry. 1996;661:61–70.Google Scholar
  18. 18.
    Bartels SJ, Drake RE, McHugo GJ. Alcohol abuse, depression, and suicidal behavior in schizophrenia. Am J Psychiatry. 1992;149:394–5.PubMedGoogle Scholar
  19. 19.
    Kamali M, Kelly L, Gervin M, Browne S, Larkin C, O’Callaghan E. The prevalence of comorbid substance misuse and its influence on suicidal ideation among in-patients with schizophrenia. Acta Psychiatr Scand. 2000;101:452–6.PubMedGoogle Scholar
  20. 20.
    Cuffel BJ, Shumway M, Choulgian TL, MacDonald T. A longitudinal study of substance use and community violence in schizophrenia. J Nerv Ment Dis. 1994;182:704–8.PubMedGoogle Scholar
  21. 21.
    Fulwiler C, Grossman H, Forbes C, Ruthazer R. Early onset substance use an d community violence by outpatients with chronic mental illness. Psychiatr Serv. 1997;48:1181–5.PubMedGoogle Scholar
  22. 22.
    Kashner TM, Rader LE, Rodell DE, Beck CM, et al. Family characteristics, substance abuse, and hospitalization patterns of patients with schizophrenia. Hosp Commun Psychiatry. 1991;42:195–7.Google Scholar
  23. 23.
    Barrowclough C, Ward J, Wearden A, Gregg L. Expressed emotion and attributions in relatives of schizophrenia patients with and without substance misuse. Soc Psychiatry Psychiatr Epidemiol. 2005;40:884–91.PubMedGoogle Scholar
  24. 24.
    Salyers MP, Mueser KT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res. 2001;48:109–23.PubMedGoogle Scholar
  25. 25.
    Todd J, Green G, Harrison M, Ikuesan BA, Self C, Pevalin DJ, Baldacchino. Social exclusion in clients with comorbid mental health and substance use problems. Soc Psychiatry Psychiatr Epidemiol. 2004;39:581–7.PubMedGoogle Scholar
  26. 26.
    Drake RE, Osher FC, Wallach MA. Homelessness and dual diagnosis. Am Psychol. 1991;46:1149–58.PubMedGoogle Scholar
  27. 27.
    Menezes POR, Johnson S, Thornicroft G, Marshall J, Prosser D, Bebbington P, Kuipers E. Drug and alcohol problems among individuals with severe mental illnesses in South London. Br J Psychiatry. 1996;168:612–9.PubMedGoogle Scholar
  28. 28.
    Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia: a prospective community study. J Nerv Ment Dis. 1989;177:408–14.PubMedGoogle Scholar
  29. 29.
    Gonzalez VM, Bradizza CM, Vincent PC, Stasiewicz PR, Paas ND. Do individuals with a severe mental illness experience greater alcohol and drug-related problems? A test of the supersensitivity hypothesis. Addict Behav. 2007;32:477–90.PubMedGoogle Scholar
  30. 30.
    Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav. 1998;23:717–34.PubMedGoogle Scholar
  31. 31.
    Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychaitr Scand. 2002;106:286–90.Google Scholar
  32. 32.
    Hipwell AE, Singh K, Clark A. Substance misuse among clients with severe and enduring mental illness: service utilisation and implications for clinical management. J Ment Health. 2000;9:37–50.Google Scholar
  33. 33.
    Janssen B, Gaebel W, Haerter M, Komaharadi F, Lindel B, Weinmann S. Evaluation of factors influencing medication ­compliance in inpatient treatment of psychotic disorders. Psychopharmacology. 2006;187:229–36.PubMedGoogle Scholar
  34. 34.
    Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication non-­compliance and substance use among patients with schizophrenia. Psychiatr Serv. 1996;47:853–8.PubMedGoogle Scholar
  35. 35.
    Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci. 2003;28:48–54.PubMedGoogle Scholar
  36. 36.
    Linszen DH, Dingemans PM, Lenior ME. Cannabis use and the course of recent onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51:273–9.PubMedGoogle Scholar
  37. 37.
    Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res. 1996;20:145–51.PubMedGoogle Scholar
  38. 38.
    Bartels SJ, Teague GB, Drake RE, Clark RE, Bush PW, Noordsy DL. Substance abuse in schizophrenia: service utilization and cost. J Nerv Ment Disord. 1993;181:227–32.Google Scholar
  39. 39.
    Mueser KT, Yarnold PR, Bellack AS. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatr Scand. 1992;85:48–55.PubMedGoogle Scholar
  40. 40.
    Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry. 2006;188:237–42.PubMedGoogle Scholar
  41. 41.
    Cantwell R. Substance use and schizophrenia: effects on symptoms, social functioning and service use. Br J Psychiatry. 2003;182:324–9.PubMedGoogle Scholar
  42. 42.
    Kavanagh DJ, Waghorn G, Jenner L, Chant DC, Carr V, Evans M, et al. Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophr Res. 2004;66:115–24.PubMedGoogle Scholar
  43. 43.
    Mueser KT, Bennet M, Kushner MG. Epidemiology of substance use disorders among persons with chronic mental illnesses. In: Lehman AF, Dixon LB, editors. Double-jeopardy: chronic mental illness and substance use disorders. London: Harwood; 1995.Google Scholar
  44. 44.
    Kovasznay B, Fleischer J, Tanenberg-Karant M. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull. 1997;23:195–201.PubMedGoogle Scholar
  45. 45.
    Carey KB, Carey MP, Simons JS. Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. J Nerv Ment Dis. 2003;191:300–8.PubMedGoogle Scholar
  46. 46.
    Dixon L, Haas GH, Weiden PJ, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry. 1991;148:224–30.PubMedGoogle Scholar
  47. 47.
    Sevy S, Robinson DG, Solloway S, Alvir JM, Woerner MG, Bilder R, Goldman R, Lieberman J, Kane J. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand. 2001;104:367–74.PubMedGoogle Scholar
  48. 48.
    Caton CL, Shrout PE, Eagle PF, Opler LA, Felix A. Correlates of codisorders in homeless and never homeless indigent schizophrenic men. Psychol Med. 1994;24:681–8.PubMedGoogle Scholar
  49. 49.
    Mueser KT, Yarnold PR, Rosenberg SD, Swett C, Miles KM, Hill D. Substance use disorders in hospitalised severely mentally ill psychiatric patients: prevalence, correlates and subgroups. Schizophr Bull. 2000;26:179–92.PubMedGoogle Scholar
  50. 50.
    Mueser KT, Drake RE, Ackerson TH, Alterman AI, Miles KM, Noordsy DL. Antisocial personality disorder, conduct disorder, and substance abuse in schizophrenia. J Abnorm Psychol. 1997;106:473–7.PubMedGoogle Scholar
  51. 51.
    Mueser KT, Crocker AG, Frisman LB, Drake RE, Covell NH, Essock SM. Conduct disorder and antisocial personality disorder in persons with severe psychiatric and substance use disorders. Schizophr Bull. 2006;32:626–36.PubMedGoogle Scholar
  52. 52.
    Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet. 1987;2:1483–6.PubMedGoogle Scholar
  53. 53.
    Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction. 2005;100:612–8.PubMedGoogle Scholar
  54. 54.
    van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156:319–27.PubMedGoogle Scholar
  55. 55.
    Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Br Med J. 2005;330(7481):11.Google Scholar
  56. 56.
    Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br Med J. 2002;325:1212–3.Google Scholar
  57. 57.
    Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction. 2005;100:354–66.PubMedGoogle Scholar
  58. 58.
    Weiser M, Knobler HY, Noy S, Kaplan Z. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet. 2002;114:949–55.PubMedGoogle Scholar
  59. 59.
    Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325:1199.PubMedGoogle Scholar
  60. 60.
    Barkus EJ, Stirling J, Hopkins RS, Lewis S. Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology. 2006;39:175–8.PubMedGoogle Scholar
  61. 61.
    Dumas P, Saoud M, Bouafia S, Gutknecht C, Ecohard R, Dalery J, Rochet T, D’Amato T. Cannabis use correlates with schizotypal personality traits in health students. Psychiatry Res. 2002;109:27–35.PubMedGoogle Scholar
  62. 62.
    Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med. 2003;33:23–32.PubMedGoogle Scholar
  63. 63.
    Williams JH, Wellman JN, Rawlins JNP. Cannabis use correlates with schizotypy in healthy people. Addiction. 1996;91:869–77.PubMedGoogle Scholar
  64. 64.
    Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend. 2003;71:37–48.PubMedGoogle Scholar
  65. 65.
    van Os J, Krabbendam L, Myin-Germeys I, Delespaul P. The schizophrenia envirome. Curr Opin Psychiatry. 2005;18:141–5.PubMedGoogle Scholar
  66. 66.
    Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57:1117–27.PubMedGoogle Scholar
  67. 67.
    Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, Ramaekers JG, van Os J. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006;31:2748–57.PubMedGoogle Scholar
  68. 68.
    D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis and addiction. Biol Psychiatry. 2005;57:594–608.PubMedGoogle Scholar
  69. 69.
    Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry. 1985;142:1259–64.PubMedGoogle Scholar
  70. 70.
    Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry. 1997;4:231–44.PubMedGoogle Scholar
  71. 71.
    Addington J, Duchak V. Reasons for substance use in schizophrenia. Acta Psychiatr Scand. 1997;96:329–33.PubMedGoogle Scholar
  72. 72.
    Gearon JS, Bellack AS, Rachbeisel J, Dixon L. Drug-use behavior and correlates in people with schizophrenia. Addict Behav. 2001;26:51–61.PubMedGoogle Scholar
  73. 73.
    Goswami S, Mattoo SK, Basu D, Singh G. Substance-abusing schizophrenics: do they self-medicate? Am J Addict. 2004;13:139–50.PubMedGoogle Scholar
  74. 74.
    Spencer C, Castle D, Michie PT. Motivations that maintain substance use among individuals with psychotic disorders. Schizophr Bull. 2002;28:233–47.PubMedGoogle Scholar
  75. 75.
    Gregg L, Haddock G, Barrowclough C (2009) Self reported ­reasons for substance use in Schizophrenia: a Q methodological investigation. Ment Health Subst Use (Dual Diagnosis). 2(1):eScholar ID:1d18011.Google Scholar
  76. 76.
    Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J Nerv Ment Dis. 1987;175:641–652.PubMedGoogle Scholar
  77. 77.
    Talamo A, Centorrino F, Tondo L, Dimitri A, Hennen J, Baldessarini RJ. Comorbid substance-use in schizophrenia: relation to positive and negative symptoms. Schizophr Res. 2006;86:251–5.PubMedGoogle Scholar
  78. 78.
    Brunette MF, Mueser KT, Xie H, Drake R. Relationships between symptoms of schizophrenia and substance abuse. J Nerv Ment Dis. 1997;185:13–20.PubMedGoogle Scholar
  79. 79.
    Dervaux A, Baylé FJ, Laqueille X, Bourdel M, Le Borgne M, Olié J, Krebs M. Is substance abuse in schizophrenia related to impulsivity, sensation seeking, or anhedonia? Am J Psychiatry. 2001;158:492–4.PubMedGoogle Scholar
  80. 80.
    Bellack AS, Morrison RL, Wixted JT, Mueser KT. An analysis of social competence in schizophrenia. Br J Psychiatry. 1990;156:809–18.PubMedGoogle Scholar
  81. 81.
    Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ. Cognitive–behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial. Br J Psychiatry. 2006;188:439–48.PubMedGoogle Scholar
  82. 82.
    Fowler IL, Carr VJ, Carter NT, Lewin TJ. Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull. 1998;24:443–55.PubMedGoogle Scholar
  83. 83.
    Green B, Kavanagh DJ, Young RMCD. Reasons for cannabis use in men with and without psychosis. Drug Alcohol Rev. 2004;23:445–53.PubMedGoogle Scholar
  84. 84.
    Schofield D, Tennant C, Nash L, Degenhardt L, Cornish A, Hobbs C, Brennan G. Reasons for cannabis use in psychosis. Aust NZ J Psychiatry. 2006;40:570–4.Google Scholar
  85. 85.
    Hambrecht M, Hafner H. Substance abuse and the onset of Schizophrenia. Biol Psychiatry. 1996;40:1155–63.PubMedGoogle Scholar
  86. 86.
    Gottesman II, Shields JA. A critical review of recent adoption, twin and family studies of schizophrenia: behavioural genetics perspectives. Schizophr Bull. 1976;2:360–401.PubMedGoogle Scholar
  87. 87.
    Tsuang MT, Bar JL, Harley RM, Lyons MJ. The Harvard Twin Study of Substance Abuse: what we have learned. Harv Rev Psychiatry. 2001;9:267–79.PubMedGoogle Scholar
  88. 88.
    Noordsy DL, Drake RE, Biesanz JD, McHugo GJ. Family history of alcoholism in schizophrenia. J Nerv Ment Dis. 1994;182:651–5.PubMedGoogle Scholar
  89. 89.
    Smith MJ, Barch DM, Wolf TJ, Mamah D, Csernansky JG. Elevated rates of substance use disorders in non-psychotic siblings of individuals with schizophrenia. Schizophr Res. 2008;106:294–9.PubMedGoogle Scholar
  90. 90.
    Gershon ES, DeLisi LE, Hamovit J, Nurnberger JI, Maxwell ME, Schreiber J, Dauphinais D, Dingman CW, Guroff JJ. A controlled family study of chronic psychoses. Schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 1988;45:328–36.PubMedGoogle Scholar
  91. 91.
    Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and substance use disorder. Am J Psychiatry. 2007;164:402–8.PubMedGoogle Scholar
  92. 92.
    Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001;50:71–83.PubMedGoogle Scholar
  93. 93.
    Weiser M, Noy S. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues Clin Neurosci. 2005;7:81–5.PubMedGoogle Scholar
  94. 94.
    Fergusson DM, Horwood LJ, Lynskey MT. Parental separation, adolescent psychopathology, and problem behaviors. J Am Acad Child Adolesc Psychiatry. 1994;33:1122–31.PubMedGoogle Scholar
  95. 95.
    Kessler RC, Davis CG, Kendler KS. Childhood adversity and adult psychiatric disorder in the US national comorbidity survey. Psychol Med. 1997;27:1101–19.PubMedGoogle Scholar
  96. 96.
    Briere J, Woo R, McRae B, Foltz J, Sitzman R. Lifetime victimization history, demographics, and clinical status in female psychiatric emergency room patients. J Nerv Ment Dis. 1997;185:95–101.PubMedGoogle Scholar
  97. 97.
    Tracy JI, Josiassen RC, Bellack AS. Neuropsychology of dual ­diagnosis: understanding the combined effects of schizophrenia and substance use disorders. Clin Psychol Rev. 1995;15:67–97.Google Scholar
  98. 98.
    Blanchard JJ, Brown SA, Horan WP, Sherwood A. Substance use disorders in schizophrenia: review, integration and a proposed model. Clin Psychol Rev. 2000;20:207–34.PubMedGoogle Scholar
  99. 99.
    Barrowclough C, Haddock G, Lowens I, Allott R, Earnshaw P, Fitzsimmons M, Nothard S. Psychosis and drug and alcohol ­problems. In: Baker A, Velleman R, editors. Clinical handbook of co-existing mental health and drug and alcohol problems. London: Bruner Routledge; 2007.Google Scholar
  100. 100.
    Marlatt GA, Gordon JR. Relapse prevention: maintenance strategies in the treatment of addictive behaviours. New York: Guildford; 1985.Google Scholar
  101. 101.
    Hides L, Kavanagh DJ, Dawe S, Young RM. The influence of cannabis use expectancies on cannabis use and psychotic symptoms in psychosis. Drug Alcohol Rev. 2008;28(3):250–6.Google Scholar
  102. 102.
    Corrigan PW, Toomey R. Interpersonal problem solving and information processing in schizophrenia. Schizophr Bull. 1995;21:395–403.PubMedGoogle Scholar
  103. 103.
    Rollins AL, Bond GR, Lysaker PH. Characteristics of coping with the symptoms of schizophrenia. Schizophr Res. 1999;36:30.Google Scholar
  104. 104.
    Bowers MB, Mazure CM, Nelson JC, Jatlow PI. Psychotogenic drug use and neuroleptic response. Schizophr Bull. 1990;16:81–5.PubMedGoogle Scholar
  105. 105.
    Brady KT, Anton R, Ballenger JC, Lydiard RB, Adinoff B, Selander J. Cocaine abuse among schizophrenic patients. Am J Psychiatry. 1990;147:1164–7.PubMedGoogle Scholar
  106. 106.
    Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26:441–9.PubMedGoogle Scholar
  107. 107.
    Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol. 2000;20:94–8.PubMedGoogle Scholar
  108. 108.
    Green AI, Noordsy DL, Brunette MF, O’Keefe C. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat. 2008;34:61–71.PubMedGoogle Scholar
  109. 109.
    Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract. 2005;11:315–39.PubMedGoogle Scholar
  110. 110.
    Drake RE, Mueser KT, Brunette M, McHugo GJ. A review of treatments for people with severe mental illness and cooccurring substance use disorder. Psychiatr Rehabil J. 2004;27:360–74.PubMedGoogle Scholar
  111. 111.
    Drake RE, O’Neal EL, Wallach MA. A systematic review of psychosocial interventions for people with co-occurring substance use and severe mental disorders. J Subst Abuse Treat. 2008;34:123–38.PubMedGoogle Scholar
  112. 112.
    Mueser KT, Drake RE, Sigmon SC, Brunette M. Psychosocial interventions for adults with severe mental illnesses and co-occurring substance use disorders: a review of specific interventions. J Dual Diagn. 2005;1:57–82.Google Scholar
  113. 113.
    Cleary M, Hunt GE, Matheson SL, Siegfried N, Walter G. Psychosocial interventions for people with both severe mental ­illness and substance misuse. Cochrane Database Syst Rev. 2008;Issue 1.Google Scholar
  114. 114.
    Tsuang J, Fong TW, Lesser I. Psychosocial treatment of patients with schizophrenia and substance abuse disorders. Addict Disord Their Treat. 2006;5:53–66.Google Scholar
  115. 115.
    Graeber DA, Moyers TB, Griffiths C, Guajardo E, Tonigan S. A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Commun Ment Health J. 2003;39:189–202.Google Scholar
  116. 116.
    Hulse GK, Tait RJ. Six-month outcomes associated with a brief alcohol intervention for adult in-patients with psychiatric disorders. Drug Alcohol Rev. 2002;21:105–12.PubMedGoogle Scholar
  117. 117.
    Kavanagh DJ, Young R, White A, Saunders JB, Wallis J, Shocklewy N, et al. A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Rev. 2004;23:151–5.PubMedGoogle Scholar
  118. 118.
    Swanson AJ, Pantalon MV, Cohen KR. Original interviewing and treatment adherence among psychiatric and dually diagnosed patients. J Nerv Ment Dis. 1999;187:630–5.PubMedGoogle Scholar
  119. 119.
    Edwards J, Elkins K, Hinton M, Harrigan SM, Donovan K, Athanasopoulos O, et al. Randomized controlled trial of a cannabis-focused intervention for young people with first-episode ­psychosis. Acta Psychiatr Scand. 2006;114:109–17.PubMedGoogle Scholar
  120. 120.
    Naeem F, Kingdon D, Turkington D. Cognitive behaviour therapy for schizophrenia in patients with mild to moderate substance misuse problems. Cogn Behav Ther. 2005;34:207–15.PubMedGoogle Scholar
  121. 121.
    Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O’Brien R, Schofield N, McGovern J. Randomised controlled trial of cognitive behavioural therapy plus motivational intervention for schizophrenia and substance use. Am J Psychiatry. 2001;158:1706–13.PubMedGoogle Scholar
  122. 122.
    Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, Sly K, Devir H, Terry M. Motivational interviewing among psychiatric in-patients with substance use disorders. Acta Psychiatr Scand. 2002;106:233–40.PubMedGoogle Scholar
  123. 123.
    Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A ­randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry. 2006;63:426–32.PubMedGoogle Scholar
  124. 124.
    Hellerstein DJ, Rosenthal RN, Miner CR. Integrated outpatient treatment for substance-abusing schizophrenics: a prospective study. Am J Addict. 1995;4:33–42.Google Scholar
  125. 125.
    Jerrell JM, Ridgely MS. Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders. J Nerv Ment Dis. 1995;183:566–76.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Clinical Psychology, School of Psychological SciencesUniversity of ManchesterManchesterUK

Personalised recommendations